MAIA
MAIA Biotechnology, Inc. AMEX Listed Jul 28, 2022$1.41
+4.44%
vs $1.35
Mkt Cap $45.3M
52w Low $0.87
25.9% of range
52w High $2.95
50d MA $1.33
200d MA $1.50
P/E (TTM)
—
EV/EBITDA
—
P/B
19.1x
Debt/Equity
0.0x
ROE
-942.7%
P/FCF
-2.4x
RSI (14)
55.10
ATR (14)
$0.08
Beta
0.32
50d MA
$1.33
200d MA
$1.50
Avg Volume
864.4K
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
444 West Lake Street · Chicago, IL 60606 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.13 | -0.08 | +38.5% | 1.49 | +0.0% | -3.4% | +2.1% | -6.1% | -5.1% | +0.0% | — |
| Nov 7, 2025 | AMC | -0.19 | -0.27 | -42.1% | 1.12 | +0.9% | +2.7% | -2.6% | -4.5% | -5.6% | +3.0% | — |
| Aug 11, 2025 | AMC | -0.24 | -0.18 | +25.0% | 1.49 | +1.3% | +5.4% | +1.9% | -2.5% | +1.3% | +0.0% | — |
| May 9, 2025 | AMC | -0.18 | -0.16 | +11.1% | 2.04 | -1.0% | -5.9% | -5.2% | -3.3% | +0.6% | +1.7% | — |
| Mar 21, 2025 | AMC | -0.20 | -0.17 | +15.0% | 1.76 | -3.4% | -5.1% | -6.0% | +5.1% | -1.2% | -0.6% | — |
| Nov 12, 2024 | AMC | -0.32 | -0.11 | +65.6% | 2.62 | -0.8% | -8.8% | -10.9% | +6.1% | +4.0% | -6.8% | — |
| Aug 9, 2024 | AMC | -0.33 | -0.17 | +48.5% | 2.66 | -4.5% | +1.5% | +1.5% | +1.1% | +2.9% | +3.9% | — |
| May 14, 2024 | AMC | -0.33 | -0.46 | -39.4% | 2.84 | +1.1% | +1.1% | +8.7% | +6.1% | +3.0% | +6.2% | — |
| Mar 21, 2024 | AMC | -0.35 | -0.41 | -17.1% | 1.94 | +1.0% | +8.8% | +20.9% | -4.3% | +1.6% | -11.3% | — |
| Nov 7, 2023 | AMC | -0.38 | -0.36 | +5.3% | 2.25 | -4.4% | -7.6% | -0.5% | -3.9% | -12.6% | +6.9% | — |
| Aug 8, 2023 | AMC | -0.43 | -0.35 | +18.6% | 2.10 | +1.8% | +1.4% | -2.8% | +0.5% | -1.4% | -1.5% | — |
| May 8, 2023 | AMC | -0.40 | -0.38 | +5.0% | 2.65 | +1.9% | +1.5% | +0.7% | -5.9% | -2.4% | +8.4% | — |
No analyst ratings available.
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Gryaznov SergeiOff | Chief Scientific Officer | Buy | 2,000 | $1.34 | $3K | 46,511 | +5.93% | +2.36% |
| Jun 1, 2026 | Smith StanDir | — | Buy | 75,000 | $1.34 | $100K | 1,519,178 | +5.93% | +2.36% |
| Jun 1, 2026 | Vitoc VladDir/Off | Chief Executive Officer | Buy | 72,700 | $1.39 | $101K | 976,121 | +5.93% | +2.36% |
8-K
MAIA Biotechnology, Inc. -- 8-K Filing
May 22
8-K
Unknown — 8-K Filing
I need actual filing content to provide meaningful analysis. This excerpt only contains standard forward-looking statement disclaimers without substantive business information about Maia Biotechnology (MAIA), preventing me from assessing material impact on the stock.
Apr 16
8-K
Unknown — 8-K Filing
I cannot provide meaningful analysis based on this fragment, as it only contains boilerplate disclaimer language about forward-looking statements with no substantive business information disclosed.
Apr 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
I need more specific information about the executive change at MAIA to provide meaningful analysis. The provided text only contains standard forward-looking statement disclaimers without details on who departed, their role, or replacement plans.
Could you provide the actual executive change details?
Apr 2
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis with only boilerplate forward-looking statement disclaimers; please provide the actual material event details from the 8-K filing for MAIA.
Mar 31
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing content is corrupted or incomplete—only metadata and file headers are visible, not the actual announcement details needed to assess impact on MAIA stock.
Mar 27
8-K · 8.01
!! High
MAIA Biotechnology, Inc. -- 8-K 8.01: Material Event / Announcement
MAIA Biotechnology announced a new securities offering on March 2, 2026, potentially raising capital for clinical development or operational expenses.
Mar 4
8-K
MAIA Biotechnology, Inc. -- 8-K Filing
MAIA Biotechnology disclosed forward-looking statement disclaimers, indicating management acknowledges inherent uncertainty in projections and estimates guiding investor expectations.
Feb 24
Institutional (13F) — Top 15
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.p. | 2,500,000 | $4M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 2,074,045 | $3M | New | Mar 2026 |
| 3 | Jane Street Group, Llc | 78,757 | $120K | New | Dec 2025 |
| 4 | Northern Trust Corp | 52,539 | $74K | Added | Mar 2026 |
| 5 | Ubs Group Ag | 51,917 | $73K | Added | Mar 2026 |
| 6 | Wealth Enhancement Advisory Services, Llc | 14,800 | $23K | — | Dec 2025 |
| 7 | Centerpoint Advisory Group | 15,730 | $22K | — | Mar 2026 |
| 8 | Catalyst Funds Management Pty Ltd | 10,800 | $15K | New | Mar 2026 |
| 9 | Daytona Street Capital Llc | 7,500 | $10K | — | Mar 2026 |
| 10 | Morgan Stanley | 2,000 | $3K | Added | Dec 2025 |
| 11 | Curio Wealth, Llc | 2,000 | $3K | — | Mar 2026 |
| 12 | Citigroup Inc | 1,738 | $3K | Added | Dec 2025 |
| 13 | Srh Advisors, Llc | 653 | $999 | New | Dec 2025 |
| 14 | Fmr Llc | 2 | $2 | New | Mar 2026 |
| 15 | Royal Bank Of Canada | 268 | — | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 169,333 | $383K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 50,558 | $114K | Feb 2026 |
| 3 | iShares Micro-Cap ETF | 76,143 | $107K | Mar 2026 |
| 4 | Fidelity Series Total Market Index Fund | 43,314 | $98K | Feb 2026 |
| 5 | Ultra-Small Company Market Fund | 36,000 | $50K | Mar 2026 |
Valuation
Market Cap
$45.3M
Enterprise Value
-$8.61B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.07x
P/B
19.05x
P/S
—
P/FCF
-2.40x
EV/EBITDA
—
Shares Out
32.1M
Financials (TTM)
Revenue
$0
Net Income
-$24.2M
EBITDA
-$14.9M
Free Cash Flow
-$18.8M
Op Cash Flow
-$18.8M
EPS Basic
$-0.70
EPS Diluted
$-0.68
EPS Forward
$-0.69
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$9.7M
Total Liab.
$7.3M
Total Equity
$2.4M
Cash
$8.66B
LT Debt
$0
Book Value/Sh
$0.07
Debt/Equity
0.00x
Current Ratio
1.66
Quick Ratio
1.66
Returns & Growth
ROE
-942.7%
ROA
-230.8%
ROIC
-627.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+33.3%
Price Returns
2W
+2.2%
1M
+4.5%
3M
-38.5%
6M
+17.8%
12M
-22.3%
Technicals
52W High
$2.95
52W Low
$0.87
50d MA
$1.33
200d MA
$1.50
RSI (14)
55.10
ATR (14)
$0.08
Beta
0.32
Avg Volume
864K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 8:25pm
· Source: financialmodelingprep.com